Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
May 05 2022 - 7:00AM
Business Wire
Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical
company focused on novel and targeted oncology therapies, today
announced the appointment of Brittany Bradrick to its Board of
Directors. Brittany is an accomplished leader with 25 years of
finance, strategy and corporate development experience.
“It’s my pleasure to welcome Brittany to our Board of Directors
at this important next stage in Spectrum’s evolution,” stated
William Ashton, Chairman of the Board of Spectrum Pharmaceuticals.
“As a seasoned executive in M&A and the life sciences sector,
Brittany’s experience and leadership will make an immediate impact
on our board.”
“I am looking forward to joining Spectrum’s Board at a time when
the company has two product candidates that are under FDA review
and approaching potential commercialization,” said Ms. Bradrick. “I
intend to add value and contribute to the company's mission of
developing and delivering innovative medicines for patients with
cancer.”
Ms. Bradrick has served as the Chief Financial Officer of
Neurelis, Inc. since October 2021. Prior to joining Neurelis, Ms.
Bradrick was Chief Operating Officer and Chief Financial Officer at
ViaCyte. She previously served in strategy and corporate
development positions for 10 years at Insulet Corporation as Vice
President, Strategy & Corporate Development and at Abbott
Diabetes Care as the Head of Global Business Development. Prior to
these positions, Ms. Bradrick was an investment banker for the life
sciences sector at Piper Jaffray, Credit Suisse, and Chase
Securities for 10 years. Ms. Bradrick began her career as a Federal
Reserve Bank Examiner. Ms. Bradrick holds an MBA from the Johnson
Graduate School of Management at Cornell University and a B.S. in
Business Administration from the University of Missouri.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel and targeted
oncology therapies. Spectrum has a strong track record of
successfully executing across the biopharmaceutical business model,
from in-licensing and acquiring differentiated drugs, clinically
developing novel assets, successfully gaining regulatory approvals
and commercializing in a competitive healthcare marketplace.
Spectrum has a late-stage pipeline with novel assets that serve
areas of unmet need. This pipeline has the potential to transform
the company in the near future. For additional information on
Spectrum Pharmaceuticals please visit www.sppirx.com.
Notice Regarding Forward-looking Statements
This press release may contain forward-looking statements
regarding future events and the future performance of Spectrum
Pharmaceuticals that involve risks and uncertainties that could
cause actual results to differ materially. These statements are
based on management's current beliefs and expectations. These
statements include, but are not limited to, statements that relate
to Spectrum’s business and its future, including certain company
milestones, Spectrum's ability to identify, acquire, develop and
commercialize a broad and diverse pipeline of late-stage clinical
and commercial products, the timing and results of FDA decisions,
and any statements that relate to the intent, belief, plans or
expectations of Spectrum or its management, or that are not a
statement of historical fact. Risks that could cause actual results
to differ include the possibility that Spectrum’s existing and new
drug candidates may not prove safe or effective, the possibility
that our existing and new applications to the FDA and other
regulatory agencies may not receive approval in a timely manner or
at all, the possibility that our existing and new drug candidates,
if approved, may not be more effective, safer or more cost
efficient than competing drugs, the possibility that our efforts to
acquire or in-license and develop additional drug candidates may
fail, our dependence on third parties for clinical trials,
manufacturing, distribution and quality control and other risks
that are described in further detail in the company's reports filed
with the Securities and Exchange Commission. The company does not
plan to update any such forward-looking statements and expressly
disclaims any duty to update the information contained in this
press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2022 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220505005165/en/
Robert Uhl Managing Director, ICR Westwicke 858.356.5932
robert.uhl@westwicke.com
Tom Riga Chief Executive Officer 949.788.6700
InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024